Showing session: reset
Advances in Precision Cancer Medicine
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors
Vivek Subbiah
Department of Investigational Cancer Therapeutics The University of MD Anderson Cancer Texas, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Alexander E Drilon
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
Alice T. Shaw
Massachusetts General Hospital, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Christine M. Lovly
Vanderbilt Univ. School of Medicine, Nashville, TN, United States
- Free
- slides video
- audio + slides
- All slides included
Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 "CREATE"
Patrick Schoffski
Catholic Univ. of Leuven - Leuven Cancer Inst., Leuven, Belgium
- Free
- slides video
- audio + slides
- All slides included
Discussant
Benjamin J Solomon
Peter MacCallum Cancer Ctr., Melbourne, Australia
- Free
- slides video
- audio + slides
- All slides included
A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors
Komal Jhaveri
Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Timothy A Yap
The University of Texas MD Anderson Cancer Center, Houston, TX, United States